(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin (R) (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.
Contents:
Part I. Introduction
Overview of Novel Anticancer Drug Targets
John K. Buolamwini and Haregewein Assefa
Part II. Kinase Inhibitor Discovery Protocols
Biomarker Assays for Phosphorylated MAP Kinase: Their Utility for Measurement of MEK Inhibition
Judith S. Sebolt-Leopold, Keri Van Becelaere, Kenneth Hook, and Roman Herrera
Assays for Cyclin-Dependent Kinase Inhibitors
Adrian M. Senderowicz and Tyler Lahusen
Identifying Inhibitors of ATM and ATR Kinase Activities
Jann N. Sarkaria
Part III. Angiogenesis and Metastasis Protocols
The Rat Aortic Ring Assay for In Vitro Study of Angiogenesis
Ronald S. Go and Whyte G. Owen
Real Time In Vivo Quantitation of Tumor Angiogenesis
Gregory I. Frost and Per Borgstroem
Use of Tumor-Activated Hepatic Stellate Cell as a Target for the Preclinical Testing of Anti-Angiogenic Drugs Against Hepatic Tumor Development
Elvira Olaso and Fernando Vidal-Vanaclocha
Cell Motility, Adhesion, Homing, and Migration Assays in the Studies of Tyrosine Kinases
Martin Sattler, Elizabeth Quackenbush, and Ravi Salgia
Inflammatory Response of Tumor-Activated Hepatic Sinusoidal Endothelium as a Target for the Screening of Metastasis Chemopreventive Drugs
Lorea Mendoza and Fernando Vidal-Vanaclocha
Binding Assay for Selectins
Jianing Zhang and Michiko N. Fukuda
Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine
Jacquelyn A. Hank, Jean E. Surfus, Jacek Gan, Amy Ostendorf, Stephen D. Gillies, and Paul M. Sondel
Part IV. Immunohistochemical Assays in the Clinical Setting
Immunohistochemical Determination of EGFR-Tyrosine Kinase Inhibition in Clinical Samples
Shazli N. Malik, Roble G. Bedolla, Manuel Hidalgo, Michael G. Brattain, and Jeffrey I.Kreisberg
Immunohistochemical Assays of Farnesyltransferase Inhibition in Patient Samples
Alex A. Adjei
Part V. Protein Chaperoning/Degradation Protocols
Assays for HSP90 and Inhibitors
Wynne Aherne, Alison Maloney, Chris Prodromou, Martin G. Rowlands, Anthea Hardcastle, Katherine Boxall, Paul Clarke, Michael I. Walton, Laurence Pearl, and Paul Workman
Assays for Proteasome Inhibition
Peter J. Elliott, Teresa A. Soucy, Christine S. Pien, Julian Adams, and Eric S. Lightcap
Part VI. Protein-Protein and Protein-DNA Interactions
The Mammalian Two-Hybrid Assay for Detection of Coactivator-Nuclear Receptor Interactions
Curtis M. Tyree and Kay Klausing
Preparation of DNA-Protein Complexes Suitable for Spectroscopic Analysis
Nouri Neamati, Manisha Murthy, and Yun-Xing Wang
Part VII. Antisense
Antisense Oligonucleotide Inhibitors of MDM2 Oncogene Expression
Ruiwen Zhang and Hui Wang
Part VIII. Genomics
Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms
Christine M. Rose, Sharon Marsh, Margaret-Mary Ameyaw, and Howard L. McLeod
Gene Expression Microarrays
Christopher P. Kolbert, William R. Taylor, Kelly L. Krajnik, and Dennis J. O'Kane
Methods for Isolation and Genetic Analysis of Circulating Tumor DNA in Patient Plasma
Tomoya Kawaguchi, Will S. Holland, and Paul H. Gumerlock
Part IX. Cell Lifespan/Longevity
The Use of Early Sea Urchin Embryos in Anticancer Drug Testing
David Nishioka, Vanessa Marcell, Meghan Cunningham, Merium Khan, Daniel D. Von Hoff, and Elzbieta Izbicka
Part X. In Vivo Imaging
PET Screening of Anticancer Drugs: A Faster Route to Drug/Target Evaluations In Vivo
Anna Fredriksson and Sharon Stone-Elander
Part XI. Miscellaneous Protocols
Assays for In Vitro and In Vivo Synergy
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: August, 2013
Pages: 355
Weight: 550g
Availability: Available
Subcategories: Pharmacology
From the same series
